Autism - Drug Pipeline Analysis and Market Forecasts to 2016

This publication has been discontinued on September 9, 2011.

Introduction

Abstract

Autism - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Autism - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global autism market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global autism market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global autism sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global autism market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data, providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include 5-HT2A and D2 receptors antagonists, serotonin inhibitors, glutamate antagonists, antioxidants, cholinergic agents and immune response down regulators.
- Analysis of the current and future market competition in the global autism market. Key market players covered are Repligen Corporation, BioMarin Pharmaceuticals, and Neuropharm Group Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with autism.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global autism market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global autism market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global autism market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Autism Market: Market Characterization 5
2.1 Overview 5
2.2 Autism Therapeutics Market Size 5
2.3 Autism Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Autism Therapeutics Market 7
2.4.1 Drivers for the Autism Therapeutics Market 7
2.4.2 Barriers for the Autism Therapeutics Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Autism Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in the Autism Therapeutics Market 10
3.3.1 Risperdal 10
3.3.2 Abilify 11
3.4 Key Takeaway 12
4 Autism Market: Pipeline Assessment 13
4.1 Overview 13
4.2 Strategic Pipeline Assessment 13
4.2.1 Technology Trends Analytic Framework 13
4.3 Autism Therapeutics - Promising Drugs under Clinical Development 14
4.4 Molecule Profile for Promising Drugs under Clinical Development 14
4.4.1 Galantamine 14
4.4.2 Atomoxetine 15
4.4.3 Fluoxetine 15
4.5 Autism Market - Clinical Pipeline by Mechanism of Action 16
4.6 Autism Pipeline - Pipeline by Clinical Phases of Development 17
4.6.1 Autism Disorder Therapeutics - Phase III Clinical Pipeline 17
4.6.2 Autism Therapeutics - Phase II Clinical Pipeline 18
4.6.3 Autism Therapeutics - Phase I Clinical Pipeline 19
4.6.4 Autism Therapeutics - Discovery Pipeline 19
4.7 Key Takeaway 19
5 Autism Market: Implications for Future Market Competition 20
6 Autism Market: Future Players in the Autism Market 21
6.1 Introduction 21
6.2 Repligen Corporation 21
6.2.1 Overview 21
6.2.2 Major Products and Services 21
6.2.3 Autism Disease Portfolio 22
6.2.4 RG1068 22
6.3 BioMarin Corporation 22
6.3.1 Overview 22
6.3.2 Major Products and Services 22
6.3.3 Autism Disease Portfolio 23
6.3.4 Kuvan 23
6.4 Neuropharm Group PLC 23
6.4.1 Overview 23
6.4.2 Major Products and Services 23
6.4.3 Autism Disease Portfolio 24
6.4.4 Fluoxetine 24
7 Autism Market: Appendix 25
7.1 Definitions 25
7.2 Acronyms 25
7.3 Research Methodology 25
7.3.1 Coverage 26
7.3.2 Secondary Research 26
7.3.3 Forecasting 27
7.3.4 Primary Research 29
7.3.5 Expert Panel Validation 30
7.4 Contact Us 30
7.5 Disclaimer 30
7.6 Sources 30

1.1 List of Tables
Table 1: Autism Market, Global, Revenues ($m), 2001-2009 6
Table 2: Autism Market, Global, Revenue($m) Forecasts, 2009-2016 7
Table 3: Major Marketed Products Comparison in the Autism Therapeutics Market, 2010 12
Table 4: Autism Therapeutics - Most Promising Drugs Under Clinical Development, 2010 14
Table 5: Autism Therapeutics - Phase III Clinical Pipeline, 2010 17
Table 6: Autism Therapeutics - Phase II Clinical Pipeline, 2010 18
Table 7: Autism Therapeutics - Phase I Clinical Pipeline, 2010 19
Table 8: Autism Therapeutics - Discovery Pipeline, 2010 19
Table 9: Repligen Corporation - Autism Pipeline Products, 2010 22
Table 10: BioMarin Corporation - Autism Pipeline Products, 2010 23
Table 11: NeuroPharm Corporation - Autism Pipeline Products, 2010 24

1.2 List of Figures
Figure 1: Autism Market, Global, Revenues ($m), 2001-2009 6
Figure 2: Autism Market, Global, Revenue ($m) Forecasts, 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Autism Therapeutics Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Autism Therapeutics, 2010 10
Figure 5: Technology Trends Analytic Framework of the Autism Therapeutics Pipeline, 2010 13
Figure 6: Technology Trends Analytic Framework of the Autism Therapeutics Pipeline - Description, 2010 14
Figure 7: Autism Market - Clinical Pipeline by Mechanism of Action, 2010 16
Figure 8: Autism Therapeutics Pipeline by Phase of Clinical Development, 2010 17
Figure 9: Implications for Future Market Competition in the Autism Market, 2010 20
Figure 10: Autism Therapeutics Market - Clinical Pipeline by Company, 2010 21
Figure 11: GlobalData Methodology 26
Figure 12: GlobalData Market Forecasting Model 29

Related Reports